Dr. Bhalla is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5323 Harry Hines Boulevard
Dallas, TX 75390Phone+1 214-645-4673Fax+1 214-648-1955
Education & Training
Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 2018 - 2021- Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 2015 - 2018
University of Florida College of MedicineClass of 2015
Certifications & Licensure
TX State Medical License 2021 - 2026
NY State Medical License 2017 - 2021- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Phase 2 Trial of Afatinib Plus Prednisone for Advanced Squamous NSCLC Start of enrollment: 2021 Aug 04
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- Concerning Safety and Efficacy of Concurrent and Consolidative Durvalumab With Thoracic Radiation Therapy in PDL1-Unselected Stage III Non-Small Cell Lung Cancer: Brie...Yuanyuan Zhang, Puneeth Iyengar, Steven Montalvo, Kenneth D Westover, Sawsan Rashdan
International Journal of Radiation Oncology, Biology, Physics. 2025-01-01 - Racial Differences in Systemic Immune Parameters in Individuals With Lung Cancer.Mitchell S von Itzstein, Jialiang Liu, Hong Mu-Mosley, Farjana Fattah, Jason Y Park
JTO Clinical and Research Reports. 2025-01-01 - Characteristics of Lung Cancer Patients With Asymptomatic or Undiagnosed SARS-CoV-2 Infections.Medha Somisetty, Philip C Mack, Chih-Yuan Hsu, Yuanhui Huang, Jorge E Gomez
Clinical Lung Cancer. 2024-11-01
Press Mentions
AI Tool May Predict Lung Cancer with 94% Accuracy with 1 Year of ScreeningJanuary 20th, 2023
Routine COVID-19 Screening Unnecessary for Cancer OutpatientsFebruary 19th, 2021
PD-L1 as a Biomarker of Response to Immune-Checkpoint InhibitorsFebruary 12th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
